Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 85% based on the firm’s underlying fundamentals and the stock’s valuation.

On Friday, Pfizer Inc (PFE) stock saw a decline, ending the day at $26.59 which represents a decrease of $-0.02 or -0.08% from the prior close of $26.61. The stock opened at $26.7 and touched a low of ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 85% based on the firm’s underlying fundamentals and the stock’s valuation.

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) were down 0.2% during trading on Friday . The company traded as low as $26 ...

Oliver Luxxe Assets LLC lifted its position in Pfizer Inc. (NYSE:PFE – Free Report) by 2.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange ...

Pfizer's stock has plummeted due to declining COVID-19 sales, expected patent losses, and political pressures, despite a high 6.45% dividend yield. PFE's strong economic moat is threatened by ...

Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $26.53 which represents a slight increase of $0.11 or 0.42% from the prior close of $26.42. The stock opened at $26.4 and touched a low of ...

Check the time stamp on this data. Updated AI-Generated Signals for Pfizer Inc. (PFE) available here: PFE.

Volume analysis indicates recent institutional ... I would consider buying additional shares of Pfizer Inc. stock if PFE can close above its 30-week EMA. Analyst’s Disclosure: I/we have a ...

Pfizer (PFE) has recently been on Zacks.com's list ... stream of earnings is what determines the fair value for its stock. Our analysis is essentially based on how sell-side analysts covering ...